$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024007376 Filed on February 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$80.80M	$46.54M	$108.1M
YoY Change	399.32%	219.68%	124.7%
% of Gross Profit
Research & Development	$71.24M	$70.64M	$272.4M
YoY Change	14.61%	-0.14%	10.96%
% of Gross Profit
Depreciation & Amortization	$168.0K	$142.0K	$527.0K
YoY Change	35.48%	10.08%	12.85%
% of Gross Profit
Operating Expenses	$152.0M	$117.2M	$380.5M
YoY Change	94.08%	37.37%	29.61%
Operating Profit	-$152.0M	-$117.2M	-$380.5M
YoY Change	94.08%	37.37%	29.61%
Interest Expense	$3.838M	$3.971M	$12.71M
YoY Change	64.3%	136.09%	220.69%
% of Operating Profit
Other Income/Expense, Net		$0.00	$0.00
YoY Change
Pretax Income	-$147.5M	-$112.2M	-$373.6M
YoY Change	91.87%	30.6%	26.5%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$147.5M	-$112.2M	-$373.6M
YoY Change	91.81%	30.6%	26.47%
Net Earnings / Revenue
Basic Earnings Per Share	-$7.38	-$5.68	-$19.99
Diluted Earnings Per Share	-$7.38	-$5.68	-$19.99
COMMON SHARES
Basic Shares Outstanding	19.90M shares	19.74M	18.69M shares
Diluted Shares Outstanding	20.00M shares	19.76M shares	18.69M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.059B	$634.1M	$634.1M
YoY Change	221.44%	76.75%	76.75%
Cash & Equivalents	$622.5M	$99.92M	$97.19M
Short-Term Investments	$436.5M	$534.2M	$534.2M
Other Short-Term Assets	$14.04M	$3.150M	$3.150M
YoY Change	676.7%	21.39%	21.39%
Inventory	$854.0K	$0.00
Prepaid Expenses
Receivables		$0.00
Other Receivables
Total Short-Term Assets	$1.074B	$637.3M	$637.3M
YoY Change	224.18%	76.35%	76.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.742M	$1.553M	$3.266M
YoY Change	240.23%	158.4%	171.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$8.328M	$3.266M	$3.266M
YoY Change	614.85%	171.49%	171.49%
TOTAL ASSETS
Total Short-Term Assets	$1.074B	$637.3M	$637.3M
Total Long-Term Assets	$8.328M	$3.266M	$3.266M
Total Assets	$1.082B	$640.5M	$640.5M
YoY Change	225.55%	76.67%	76.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.53M	$28.04M	$28.04M
YoY Change	77.51%	17.67%	17.67%
Accrued Expenses	$92.27M	$89.98M	$90.51M
YoY Change	7.83%	-1.62%	-1.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$114.3M	$118.5M	$118.5M
YoY Change	16.26%	2.29%	2.29%
LONG-TERM LIABILITIES
Long-Term Debt	$116.1M	$115.5M	$115.5M
YoY Change	38.31%	134.29%	134.29%
Other Long-Term Liabilities	$1.045M	$1.186M	$1.186M
YoY Change
Total Long-Term Liabilities	$117.2M	$116.7M	$116.7M
YoY Change	39.56%	136.7%	136.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$114.3M	$118.5M	$118.5M
Total Long-Term Liabilities	$117.2M	$116.7M	$116.7M
Total Liabilities	$231.5M	$235.2M	$235.2M
YoY Change	26.99%	42.4%	42.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.484B	-$1.336B
YoY Change	42.67%	38.81%
Common Stock	$2.335B	$1.741B
YoY Change	96.24%	50.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$850.8M	$405.3M	$405.3M
YoY Change
Total Liabilities & Shareholders Equity	$1.082B	$640.5M	$640.5M
YoY Change	225.55%	76.67%	76.67%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$147.5M	-$112.2M	-$373.6M
YoY Change	91.81%	30.6%	26.47%
Depreciation, Depletion And Amortization	$168.0K	$142.0K	$527.0K
YoY Change	35.48%	10.08%	12.85%
Cash From Operating Activities	-$149.2M	-$79.93M	-$324.2M
YoY Change	77.43%	36.6%	44.19%
INVESTING ACTIVITIES
Capital Expenditures	$357.0K	$1.036M	$1.479M
YoY Change	920.0%	3472.41%	581.57%
Acquisitions
YoY Change
Other Investing Activities	$98.41M	-$361.1M	-$501.0M
YoY Change	-152.67%	-643.67%	-342.16%
Cash From Investing Activities	$98.05M	-$362.1M	-$502.5M
YoY Change	-152.47%	-645.47%	-343.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$573.7M	479.9M	$595.1M
YoY Change	988.83%	81.55%	89.86%
NET CHANGE
Cash From Operating Activities	-$149.2M	-79.93M	-$324.2M
Cash From Investing Activities	$98.05M	-362.1M	-$502.5M
Cash From Financing Activities	$573.7M	479.9M	$595.1M
Net Change In Cash	$522.6M	37.86M	-$231.6M
YoY Change	-339.46%	-86.09%	-178.45%
FREE CASH FLOW
Cash From Operating Activities	-$149.2M	-$79.93M	-$324.2M
Capital Expenditures	$357.0K	$1.036M	$1.479M
Free Cash Flow	-$149.5M	-$80.97M	-$325.7M
YoY Change	77.78%	38.3%	44.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001157601
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-33277
CY2023	dei	Entity Registrant Name EntityRegistrantName	MADRIGAL PHARMACEUTICALS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3508648
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Four Tower Bridge
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	200 Barr Harbor Drive, Suite 200
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	West Conshohocken
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19428
CY2023	dei	City Area Code CityAreaCode	267
CY2023	dei	Local Phone Number LocalPhoneNumber	824-2827
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 Par Value Per Share
CY2023	dei	Trading Symbol TradingSymbol	MDGL
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	3158123661	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19897425	shares
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	true
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99915000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	331549000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	534216000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	27225000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3150000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2595000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	637281000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	361369000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1553000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	601000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1713000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	602000	usd
CY2023Q4	us-gaap	Assets Assets	640547000	usd
CY2022Q4	us-gaap	Assets Assets	362572000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	28041000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	23831000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89980000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91461000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	527000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	602000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	118548000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	115894000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	115480000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	49289000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1186000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	116666000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	49289000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	235214000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	165183000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2369797	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2369797	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2369797	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2369797	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19875427	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19875427	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18102523	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18102523	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1741153000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1160079000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	468000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-32000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1336290000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-962660000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	405333000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	197389000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	640547000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	362572000	usd
CY2023	us-gaap	Revenues Revenues	0	usd
CY2022	us-gaap	Revenues Revenues	0	usd
CY2021	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	272350000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	245441000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	205164000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	108146000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48130000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37318000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	380496000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	293571000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	242482000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-380496000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-293571000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-242482000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	19578000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2185000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	363000	usd
CY2023	us-gaap	Interest Expense InterestExpense	12712000	usd
CY2022	us-gaap	Interest Expense InterestExpense	3964000	usd
CY2021	us-gaap	Interest Expense InterestExpense	0	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	273000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-373630000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-295350000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-241846000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-19.99
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-19.99
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-17.23
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.23
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.63
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.63
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18687774	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18687774	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17137201	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17137201	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16535188	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16535188	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-373630000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-295350000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-241846000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	500000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	48000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-127000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-373130000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-295302000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-241973000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	31625000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	48000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	622000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-295350000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	197389000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	49735000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	500000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	860000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-373630000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	405333000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-373630000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-295350000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-241846000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	49735000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	31625000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	26873000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	527000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	467000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2414000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	555000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1257000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	4210000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2451000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	20363000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1481000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	36413000	usd
CY2023	mdgl	Increase Decrease In Accrued Interest Net Of Interest Received IncreaseDecreaseInAccruedInterestNetOfInterestReceived	-5450000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-183917000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	143478000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	394120000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	333398000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	350381000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	389274000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	217000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	209000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-502520000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	206686000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5055000	usd
CY2023	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	65000000	usd
CY2022	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	50000000	usd
CY2021	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	0	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	363000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	886000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	595116000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	313451000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	171237000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-231634000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	295280000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17735000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	331549000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36269000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54004000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99915000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	331549000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36269000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1628000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	583000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	376000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023	mdgl	Patent Costs PatentCosts	900000	usd
CY2022	mdgl	Patent Costs PatentCosts	500000	usd
CY2021	mdgl	Patent Costs PatentCosts	500000	usd
CY2023	mdgl	Deferred Tax Assets Percentage Of Valuation Allowance DeferredTaxAssetsPercentageOfValuationAllowance	1
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-373600000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1336300000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-962700000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	633663000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	476000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	634131000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	331549000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	331549000	usd
CY2022Q4	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	358806000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	39000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	358774000	usd
CY2023Q4	mdgl	Accrued Contract Research Costs Current AccruedContractResearchCostsCurrent	50737000	usd
CY2022Q4	mdgl	Accrued Contract Research Costs Current AccruedContractResearchCostsCurrent	53119000	usd
CY2023Q4	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	3724000	usd
CY2022Q4	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	6582000	usd
CY2023Q4	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	9705000	usd
CY2022Q4	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	11262000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17030000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14864000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6814000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4867000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1970000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	767000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89980000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91461000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14899	shares
CY2022Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	600000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4555	shares
CY2023Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	900000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	12802000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	79604000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	53387000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	145793000	usd
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	24641000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	5672000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	115480000	usd
CY2023	mdgl	Common Stock Voting Rights Number CommonStockVotingRightsNumber	1	vote
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2857054	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	81.78
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	31111	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	190.91
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	460385	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	88.83
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	72001	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	144.24
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2355779	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	79.94
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	359861000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1774976	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	74.49
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y8M15D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	281400000	usd
CY2023Q4	mdgl	Common Stock Capital Shares Granted And Issuable CommonStockCapitalSharesGrantedAndIssuable	2881896	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	49735000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31625000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26873000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	49735000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31625000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26873000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1600000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	937000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	478000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	446000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1861000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	148000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1713000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1095
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1100000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	700000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1100000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	800000	usd
CY2023	us-gaap	Revenues Revenues	0	usd
CY2021	us-gaap	Revenues Revenues	0	usd
CY2022	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1600000	usd
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	46100000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	112000000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	117000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	117000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	37000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	45000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	53000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3857000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2398000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1857000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	503000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	589000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	783000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	33976000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	27226000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	24335000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	95000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	106000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	80000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	8000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	23000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	121552000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	68305000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	47864000	usd
CY2023Q4	mdgl	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	175145000	usd
CY2022Q4	mdgl	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	137328000	usd
CY2021Q4	mdgl	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	112848000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	48074000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	35103000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	23799000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	383239000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	271108000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	211642000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	383122000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	271108000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	211642000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	117000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-78462000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-62023000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-50788000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-8287000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-7844000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0	usd
CY2023	mdgl	Effective Income Tax Rate Reconciliation162 M Limitation Amount EffectiveIncomeTaxRateReconciliation162MLimitationAmount	3183000	usd
CY2022	mdgl	Effective Income Tax Rate Reconciliation162 M Limitation Amount EffectiveIncomeTaxRateReconciliation162MLimitationAmount	7996000	usd
CY2021	mdgl	Effective Income Tax Rate Reconciliation162 M Limitation Amount EffectiveIncomeTaxRateReconciliation162MLimitationAmount	22000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	53000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	16000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	5000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-16246000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	13090000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-19622000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	112606000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	59466000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	79258000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	12971000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	10712000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	9002000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	124000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	11000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	127000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Revenues Revenues	0	usd
CY2023Q2	us-gaap	Revenues Revenues	0	usd
CY2023Q3	us-gaap	Revenues Revenues	0	usd
CY2023Q4	us-gaap	Revenues Revenues	0	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	62154000	usd
CY2023Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	68605000	usd
CY2023Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	70951000	usd
CY2023Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	70640000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16182000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17845000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27583000	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46536000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	78336000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	86450000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	98534000	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	117176000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-78336000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-86450000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-98534000	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-117176000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3776000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3551000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3298000	usd
CY2023Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	8953000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2336000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	2901000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	3504000	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	3971000	usd
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2023Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2023Q4	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-76896000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-85800000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-98740000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-112194000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.23
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.23
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.69
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.69
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.34
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.34
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.68
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.68
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18187924	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18187924	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18310952	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18310952	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18476414	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18476414	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19760842	shares
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19760842	shares
CY2022Q1	us-gaap	Revenues Revenues	0	usd
CY2022Q2	us-gaap	Revenues Revenues	0	usd
CY2022Q3	us-gaap	Revenues Revenues	0	usd
CY2022Q4	us-gaap	Revenues Revenues	0	usd
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	47929000	usd
CY2022Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	58499000	usd
CY2022Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	68271000	usd
CY2022Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	70742000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9658000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11774000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12141000	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14557000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	57587000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	70273000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	80412000	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	85299000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-57587000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-70273000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-80412000	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-85299000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	69000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	323000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	717000	usd
CY2022Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	1076000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	0	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	780000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1502000	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	1682000	usd
CY2022Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2022Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2022Q4	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-57518000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-70730000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-81197000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-85905000	usd
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.36
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.36
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.14
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.14
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.75
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.75
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.98
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.98
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17103395	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17103395	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17103395	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17103395	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17103395	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17103395	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17237517	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17237517	shares

Files In Submission

Name	View Source	Status
mdgl-20231231_lab.xml	Edgar Link	unprocessable
0001628280-24-007376-index-headers.html	Edgar Link	pending
0001628280-24-007376-index.html	Edgar Link	pending
0001628280-24-007376.txt	Edgar Link	pending
0001628280-24-007376-xbrl.zip	Edgar Link	pending
a10ormofindemnificationagr.htm	Edgar Link	pending
a20231231-ex311.htm	Edgar Link	pending
a20231231-ex312.htm	Edgar Link	pending
a20231231-ex321.htm	Edgar Link	pending
a2312023madrigalconsentlet.htm	Edgar Link	pending
a971mdglclawbackpolicy.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mdgl-20231231.htm	Edgar Link	pending
mdgl-20231231.xsd	Edgar Link	pending
mdgl-20231231_g1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
mdgl-20231231_cal.xml	Edgar Link	unprocessable
mdgl-20231231_def.xml	Edgar Link	unprocessable
mdgl-20231231_pre.xml	Edgar Link	unprocessable
mdgl-20231231_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2024 Q1 Form 10-K Financial Statement

#000162828024007376 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2024 Q1 Form 10-K Financial Statement

#000162828024007376 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl